Updates on the Environmental Triggers of Type 1 Diabetes (ADA 2020)

The onset of type 1 diabetes (T1D) usually entails a genetic predisposition to developing the condition, as well as an “environmental trigger” (such as a viral infection, or another exposures). As we previously reported, a multi-center international research effort called TEDDY (The Environmental Determinants of Diabetes in the Young) has been investigating potential environmental triggers that may induce the onset of type 1 diabetes in children since 2004.

As described in the most recent press release:

“TEDDY is aiming to discover viruses and nutritional factors that interact with genes to “trigger” immune destruction of the beta cells, marked by the appearance of islet autoantibodies. The study enrolls infants identified as “at-risk” for developing T1D and follows them for 15 years to look for the appearance of various beta-cell autoantibodies and diabetes. TEDDY has also studied biomarkers that can predict faster or slower progression to diabetes after the autoimmune destruction has begun.”

Now, new data on environmental connections between type 1 diabetes as well as celiac disease were just presented today at the American Diabetes Association (ADA) 80th Scientific Sessions. Dr. Marian Rewers, MD, PhD from the Barbara Davis Center for Diabetes at the University of Colorado School of Medicine, along with other presenters, provided the new research updates.

Key Takeaways

Here are the major highlights:

  • It appears that beta cell destruction often begins very early in life; as early as in the first two years of life.
  • There may be two distinct subtypes of type 1 diabetes that are characterized by differences in their genetics, immune system, and various metabolomic markers.
  • The value of HbA1c as a predictive factor for developing type 1 diabetes may differ between youth and adults who develop the condition.
  • Presence of enterovirus B in stool samples is predictive of islet autoimmunity development in children.
  • The gut microbiome composition tends to be different in children who develop islet autoantibodies as compared to those who do not. The use of probiotics may help to mitigate this risk.
  • Use of antibiotics WAS NOT shown to be related to autoimmunity.
  • Vitamin D, vitamin C, and polyunsaturated fats may carry preventative benefits against autoimmunity, although this needs to be validated in further studies.

Another interesting update was concerning the environmental determinants of celiac disease. There is some overlap in the genetic factors that are associated with the development of type 1 diabetes and celiac disease. Interestingly, recent research has identified a link between the consumption of gluten early in childhood and an increased risk for developing celiac disease among those with a genetic predisposition.

Dr. Rewers had this to say in summary:

“While T1D and celiac disease share a lot of genetic characteristics, there are intriguing differences in the ways these diseases develop and progress,” added Dr. Rewers. “TEDDY is contributing exciting clues for design of future trials to prevent both T1D and celiac disease.”

Conclusions

The multidisciplinary international TEDDY research effort continues to uncover important pieces of the complex puzzle to explain exactly how and why certain individuals develop type 1 diabetes and other autoimmune conditions. Understanding the relationships between genetic predispositions to autoimmune disease and how they may be triggered is critical to the development of effective preventative strategies in the future.

Stay tuned for more research updates from ADA 2020!

Source: diabetesdaily.com

New Therapy Shows Promise in Children with Newly-Onset Diabetes (ADA2020)

Research is ongoing around the world concerning the delay of progression and the prevention of type 1 diabetes. The etiology of the disease has been extensively characterized, but all the events and processes that drive and maintain autoimmune attack on the insulin-producing cells are still not fully understood.

One avenue of current investigation involves the clinical application of Tregulatory (Treg) cells. This population of immune cells have many functions, and importantly, serve to help the body recognize the self (“self-tolerance”) and to prevent aberrant attack on healthy tissues (autoimmune disease).

Dr. Piotr Trzonkowski, M.D., Ph.D from the Medical University of Gdansk in Poland has focused his career on investigating, developing, and applying cell-based therapeutic approaches. He presented his most recent work as part of the late-breaking poster session in the Diabetes Prevention category at the American Diabetes Association (ADA) 80th Scientific Sessions this weekend.

The research focuses on utilizing Treg cell therapy in combination with an antibody against a molecule called CD20. This molecule is expressed by immune cells populations (B cells) that are involved in mediating autoimmune disease (read more about anti-CD20 therapies here and about targeting B cells for type 1 diabetes therapy here).

Study Design

This phase II clinical trial utilized the combinational treatment (TrCD20) as part of a study that enrolled 36 children with a recent type 1 diabetes diagnosis. The participants were divided into three groups: control , Treg therapy alone, or the combinational therapy (TrCD20). All patients were followed for a period of two years, and various clinical parameters, such as blood glucose levels and beta cell function, were evaluated and compared between the groups.

Major Outcomes

The main finding in this study was that patients who received the combinational therapy fared better than the other groups with respect to multiple parameters, including fasting and stimulated c-peptide levels (c-peptide is a measurement of insulin production). Also, patients in both treatment groups exhibited lower HbA1c levels and lower fasting blood glucose levels throughout the study. The researchers noted that:

“TrCD20 group was in partial remission defined as insulin dose below 0.5 IU/kg up to +21 months. The longest insulin independent follow up lasted 18 months. The end of the remission in Tr group was noted at +18 month and in controls at +12 months. At the +24 months daily insulin requirement and HbA1c levels were significantly lower in TrCD20 as compared to control group.”

Conclusions

This phase II clinical trial demonstrated increased efficacy of combining cell-based therapy and antibody treatment to achieve longer beta-cell function in children with newly-diagnosed type 1 diabetes. Importantly, in addition to the potential glycemic management benefits, delaying the progression of type 1 diabetes at the early stages may also allow for the clinical application of several novel therapies aimed at halting disease progression.

For example, consider the following research that we have reported on over the last year:

Personalized Therapies for Type 1 Diabetes Take Center Stage 

TrialNet Updates: New Treatment Delays Type 1 Diabetes Onset 

“Inverse Vaccine” to Treat Type 1 Diabetes Passes Phase I Clinical Trial

We will continue to keep you posted of ongoing developments and promising new approaches. Please stay tuned for our ongoing coverage of the most recent research presented at the ADA Scientific Sessions.

Source: diabetesdaily.com

Age at Type 1 Diabetes Diagnosis Predicts Risk for Other Autoimmune Conditions

It is known that individuals with type 1 diabetes may be more likely than the general population to develop other autoimmune conditions, such as thyroid disorders. The reasons for this are complex, likely multifactorial, and the specific risk factors are still being investigated. Recently, a study sought to evaluate the prevalence of autoimmune disorders in […]
Source: diabetesdaily.com

Search

+